ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1320

Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Abstract Number: 2047

Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Abstract Number: 2095

Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)
Abstract Number: 1909

Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.
Abstract Number: 0859

Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
Abstract Number: 2061

Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis
Abstract Number: 1110

Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Abstract Number: 1907

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021
Abstract Number: 0828

Two Common AI Models Create Poor Rheumatology Board Style Questions
Abstract Number: 1594

Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1965

Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
Abstract Number: 0458

TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Abstract Number: 0943

Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Abstract Number: 0419

Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
Abstract Number: 0936

Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].